Articles tagged "Immunosuppression"

2022 American Transplant Congress
A Novel Immunosuppressive Compound (79-6) That Targets Bcl6 Prevents the Humoral Alloresponse
R. Kraaijeveld, D. A. Hesselink, C. C. Baan
Internal medicine - Nephrology and Transplantation, Erasmus Medical Center, Rotterdam, Netherlands
*Purpose: BCL6, is a transcription factor involved in B cell activation and differentiation. BCL6-expressing B cells play a crucial role in the development and maintenance…
2022 American Transplant Congress
Immunomodulation in Lung Transplant May Facilitate Transformation of Usual Interstitial Pneumonia Into Pleuroparenchymal Fibroelastosis
Q. Cai¹, K. Batra², J. R. Torrealba¹
¹Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, ²Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX
*Purpose: Pleuroparenchymal fibroelastosis (PPFE) is a rare but distinctive manifestation of interstitial lung disease (ILD) characterized by a highly elastotic pattern of lung fibrosis. Its…
2022 American Transplant Congress
Artificial Intelligence Based Dosing of Tacrolimus in Liver Transplantation: Prospective, Randomized Phase 2 Trial
A. Zarrinpar¹, C. Ho², C. Warren¹, J. Khong², M. Lee², S. Duarte¹, K. Andreoni¹, M. Johnson¹, N. Battula³, D. McKimmy¹, T. Beduschi¹
¹Surgery, University of Florida, Gainesville, FL, ²Mechanical and Aerospace Engineering, University of California, Los Angeles, CA, ³Surgery, University of Oklahoma, Oklahoma City, OK
*Purpose: Inter- and intra-individual variability in calcineurin dose requirements necessitates empirical clinician-titrated dosing that frequently results in deviation from target ranges, particularly during the critical…
2022 American Transplant Congress
Clinically Available Immunosuppressive Agents Prolong Pig-to-Primate Kidney Xenograft Survival
I. J. Anwar¹, Q. Gao¹, I. DeLaura¹, J. Yoon¹, R. Baldi¹, M. Youd², K. Stiede², K. Hall², S. Knechtle¹, J. Kwun¹
¹Surgery, Duke Transplant Center, Durham, NC, ²eGenesis Inc, Cambridge, MA
*Purpose: Most immunosuppressive regimens used in Pig-To-Primate Xenotransplantation contain anti-CD154 agents, compounds that are currently not FDA-approved. The aim of this study was to assess…
2022 American Transplant Congress
Long Term Longitudinal TTV Measurements in Lung Transplant Recipients
E. Gore¹, C. Rondaan¹, E. A. Verschuuren², L. Gard¹, H. G. Niesters¹, C. van Leer-Buter¹
¹Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ²Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
*Purpose: To investigate how levels of Torque Teno Virus (TTV), a virus which has been proposed as a marker for immunosuppression change over a period…
2022 American Transplant Congress
Impact of Belatacept Conversion on Renal Function and Donor Specific Antibodies in Renal Transplant Recipients
E. R. Brown, K. Cunningham, K. Paplaczyk, C. Dagostino, C. Kane, A. Shetty
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Although associated with nephrotoxicity, calcineurin inhibitors (CNI) have historically been the cornerstone of immunosuppression. Belatacept, a co-stimulation blocker, is FDA-approved for de novo use…
2022 American Transplant Congress
HLA-DR/DQ Single Molecule Eplet Mismatch and Formation of De Novo Donor-Specific Anti-HLA Antibodies After Kidney Transplantation in Children
V. K. Sigurjonsdottir¹, K. Piburn¹, P. C. Grimm¹, B. M. Zhang²
¹Division of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, ²Histocompatibility and Immunogenetics Laboratory, Stanford Blood Center, Palo Alto, CA
*Purpose: The advances in HLA typing methods and elucidation of three-dimensional molecular structures of HLA antigens in recent years have allowed analysis of donor/recipient HLA…
2022 American Transplant Congress
Pharmacogenomic Dosing in Kidney Transplant Patients Converted from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®)
K. D. Belfield¹, K. J. Armstrong², D. Malhotra³, G. F. Girone¹
¹Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Department of Pharmacy, Hospital of Central Connecticut, New Britain, CT, ³Section of Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: When converting from tacrolimus (tac) immediate release (tacIR) to tac extended release (Envarsus XR; tacXR), the package insert (PI) recommends 80% of the tacIR…
2022 American Transplant Congress
Evaluation of Conversion from Immediate Release (IR) Tacrolimus to LCP-Tacrolimus (Envarsus XR®, LCP) in Heart Transplant Recipients
E. Foster¹, A. Iaria¹, J. Negrelli², M. Fine², M. Yu², M. Liebo²
¹University of Illinois at Chicago, Chicago, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: The purpose of this study was to assess outcomes in heart transplant recipients who were converted from IR tacrolimus to LCPT. Limited data exists…
2022 American Transplant Congress
Variation in Immunosuppressive Regimen in Children Receiving Liver Transplants: An Analysis of the UNOS Database
V. K. Raghu¹, J. E. Squires¹, C. Confair², E. Katz-Eisenberg², G. V. Mazariegos³, E. R. Perito⁴
¹Pediatrics, University of Pittsburgh, Pittsburgh, PA, ²Starzl Network for Excellence in Pediatric Transplantation, Pittsburgh, PA, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁴Pediatrics, University of California San Francisco, San Francisco, CA
*Purpose: Optimizing immunosuppression (IS) was identified as a priority for pediatric liver transplant (LT) families and providers in the Starzl Network, a multi-center learning health…